What Botanical Solutions does

Botanical Solution Inc. (BSI) is a Delaware-incorporated biotech company founded in 2013 in Chile that has developed a proprietary, patented plant tissue culture platform to produce Advanced Botanical Materials (ABM) from in vitro Quillaja saponaria — a protected Chilean soapbark tree. The platform enables the extraction of active ingredients from laboratory-grown "baby trees" rather than harvesting mature trees, circumventing Chilean deforestation restrictions that have constrained the supply and driven up the cost of traditional botanical extracts (notably QS-21, which historically traded near $400,000 per gram).

BSI monetizes the ABM-01 active ingredient through two distinct end-products serving two separate markets. In agriculture, Quillibrium® (marketed as BotriStop® in Chile and Peru) is a broad-spectrum biofungicide for high-value fruit and vegetable crops, distributed exclusively through a global partnership with Syngenta. In pharmaceuticals, QS-21 — the "Gold Standard" vaccine adjuvant used in RSV, shingles, malaria, and COVID-19 vaccine candidates — is supplied to vaccine developers through a partnership with Croda Pharma and direct relationships. The company operates R&D and production labs in Davis, California and Santiago, Chile, and has accumulated over $23 million in Series A funding on top of a $3.3 million seed round.

The business model combines product sales (Quillibrium via Syngenta), supply/licensing agreements (QS-21 via Croda), and direct pharmaceutical sales, with enterprise field sales targeting vaccine developers and crop protection buyers. Geographic footprint currently spans Chile and Peru in agriculture, with announced expansion into Mexico, Canada, the United States, Brazil, and the EU. The company is venture-backed (Series A stage), with 11–50 employees and a board that includes former executives from GlaxoSmithKline, Dynavax, and Bayer CropScience biologics.

Name

Botanical Solutions

Legal name

Botanical Solution Inc.

Website

https://botanical-solution.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

51–100 employees

Short description

Botanical Solution Inc. (BSI) is a plant biotechnology company that uses proprietary in vitro tissue culture of Quillaja saponaria to produce Advanced Botanical Materials for two markets: Quillibrium, a biofungicide distributed by Syngenta, and QS-21, a vaccine adjuvant supplied via Croda Pharma.

Ownership category

akta.pro rank

Product category

Plant-based bioproducts (vaccine adjuvants and biopesticides)

NAICS

Pesticide and Other Agricultural Chemical Manufacturing (32532), Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Agricultural Chemicals (2870), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Botanical Biopesticides & Plant Extracts (Essential Oils, Neem, Pyrethrins) (AFABAEAF)

akta.pro secondary industries

Biological Formulation, Fermentation & Scale-Up Manufacturing (AFABAEAM), Biological Pest Control (Beneficial Insects, Nematodes, Microbials) (AFABAKAB)

Keywords

• Plant tissue culture
• Vaccine adjuvant
• Biofungicide production
• Botanical biomanufacturing
• Biopesticide crop protection

Headquarters

HQ city

Vitacura

HQ country

Chile

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical QS-21 Sales: Sale of pharmaceutical-grade vaccine adjuvant QS-21 to pharmaceutical companies and vaccine developers. BSI supplies directly and through partnership with Croda Pharma for GMP QS-21 production.
2. Agricultural Biofungicide Sales: Sale of botanical-based biofungicide Quillibrium (BotriStop in Chile) through distribution partner Syngenta. Product protects fruits and vegetables from fungal diseases.
3. Licensing and Supply Agreements: Strategic partnerships including supply agreements with Croda Pharma for QS-21 and distribution agreements with Syngenta for agricultural products.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Botanical Solution Inc. (BSI) manufactures two plant-based products from Advanced Botanical Materials (ABM) produced through its proprietary in vitro Quillaja saponaria plant tissue culture platform: QS-21, a pharmaceutical-grade vaccine adjuvant supplied to vaccine developers, and Quillibrium (BotriStop in Chile), a botanical-based biofungicide distributed to agricultural growers. The platform eliminates the need to harvest mature soapbark trees, enabling sustainable, consistent, and scalable production of both products.

Product overview

Botanical Solution Inc. (BSI) operates as a dual-market biotechnology company producing Advanced Botanical Materials (ABM) from in-vitro Quillaja saponaria plant tissue culture. The company offers two core products derived from the same ABM-01 platform: Quillibrium®, a broad-spectrum botanical biofungicide for agriculture (distributed by Syngenta), and QS-21, the Gold Standard vaccine adjuvant for human pharmaceuticals. Both products share the same plant-derived active ingredient but serve distinct markets—crop protection and vaccine development—enabled by BSI's proprietary in-lab cultivation and extraction technology that eliminates the need to harvest mature trees.

Differentiator

Problem solved

Functional benefit

Brands

• QS-21: Gold Standard vaccine adjuvant used in RSV, shingles, malaria, and other vaccines including COVID-19 vaccine candidates. Extracted from Quillaja saponaria trees.
• Quillibrium
• BotriStop
• ABM-01

Products and services

• Quillibrium® (marketed as BotriStop® in Chile) A broad-spectrum botanical-based biofungicide derived from Quillaja saponaria plant tissue culture (ABM-01) that effectively prevents and controls pathogens including Botrytis cinerea, Alternaria alternata, Sour Rot, and Powdery Mildew on fruits and vegetables including grapes, tomatoes, berries, cherries, and blueberries. Distributed exclusively by Syngenta globally; currently commercialized as BotriStop® in Chile and Peru, and under the Quillibrium® brand in Mexico, with pending EPA approval for U.S. rollout.
• QS-21 Vaccine Adjuvant The Gold Standard vaccine adjuvant extracted from BSI's tissue-cultured Quillaja saponaria (ABM-01), produced in-house under GMP standards. Used in FDA-approved human vaccines including shingles, RSV, malaria, and COVID-19 vaccine candidates, as well as in immunotherapy treatments including cancer. Sold directly to pharmaceutical companies and through the Croda Pharma supply agreement, solving the supply and cost challenges of traditional bark extraction from wild Chilean soapbark trees.
• ABM-01 (Advanced Botanical Material)

Quantifiable outcome

• Over 100,000 acres treated with Quillibrium across Chile and Peru
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Novonesis (formerly Novozymes BioAg): Global leader in industrial enzymes and microbial biosolutions including agricultural biocontrol products. Comparable as a broad incumbent in the biologicals market with overlapping biofungicide offerings and significantly larger scale and distribution reach.
• Syngenta: Global ag-inputs major with extensive crop protection portfolio including biologicals. Comparable as BSI's exclusive distribution partner for Quillibrium globally, but also a broad incumbent with in-house biopesticide capabilities that could compete or substitute.

Direct peers

• Phyton Biotech: Plant cell fermentation company producing paclitaxel and other complex plant-derived APIs via plant tissue culture. Closely comparable on the underlying production technology platform — both companies leverage plant tissue culture to manufacture traditionally plant-sourced molecules at scale.
• Bioceres: Latin American ag-biotech company developing biological inputs, including biopesticides and biofertilizers, for row and specialty crops. Comparable as a regional ag-biotech with botanical/biocontrol product lines and South American distribution footprint similar to BSI's Chilean roots.
• Symborg: Spanish-origin biopesticide and biostimulant company with global distribution in high-value crops. Direct competitor in the biofungicide/biofungicide market with comparable go-to-market through distributors and similar product positioning on sustainability.
• Adjuvance Technologies: Specialty vaccine adjuvant developer producing saponin-based adjuvants including semi-synthetic QS-21 alternatives. Closely comparable on the pharma side as a competing supplier of next-generation vaccine adjuvants to the same vaccine developer customer base.
• BioConsortia: US-based ag-biotech developing microbial and biological crop protection and enhancement products. Direct comparable in the agricultural biologicals space; notable board overlap as BioConsortia's CEO Marcus Meadows-Smith also serves on BSI's board.
• Dynavax Technologies: US vaccine developer and adjuvant supplier (CpG 1018 adjuvant used in HEPLISAV-B). Comparable as a vaccine adjuvant specialist serving the same pharma customer segment; notable personnel overlap as former Dynavax CEO Eddie Gray joined BSI's board.
• Marrone Bio Innovations (Biovent): US-based biopesticide company developing biofungicides, bioinsecticides, and bionematicides from natural sources for row crops and specialty crops. Directly comparable as a competing botanical/microbial crop protection player targeting similar fruit and vegetable disease segments.

Emerging players

• Indigo Ag: US-based ag-biotech developing microbial crop inputs and biological seed treatments. Comparable as an emerging player in agricultural biologicals with similar positioning on sustainability and grower outcomes, though focused on microbial rather than botanical actives.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/botanical-solutions-spa

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds6 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Botanical Solutions